

CombinedX - Weaker Market Hurting

Redeye sustains its positive view of CombinedX despite a weak Q3 report, leading to cuts in our 2024 and 2025 forecasts. While investors might question the quality of CombinedX's businesses following the two most recent quarters, our positive view of the six remaining subsidiaries remains intact.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[CombinedX - Weaker Market Hurting](#)